Angiogenesis in Cancer Treatment: 60 Years’ Swing Between Promising Trials and Disappointing Tribulations
Pp. 34-96 (63)
Khalid Alhazzani, Ali Alaseem, Mohammad Algahtani, Sivanesan Dhandayuthapani, Thiagarajan Venkatesan, Appu and Rathinavelu
Pathological angiogenesis plays essential role in tumor progression,
invasiveness, and metastasis. This process is highly stimulated by VEGF/VEGFR
signaling pathway(s). Additional players such as Ang/Tie-2, FGF/FGFR, and Notch
signals are also involved in this complex process by stabilization and maturation of
blood vessels. As a result of the identification of molecular pathways and various
targets driving angiogenesis, several agents have been developed for cancer treatment.
Among various pathways, targeting VEGF/VEGFR2 has been proven to be the most
effective to inhibit tumor angiogenesis and subsequent tumor growth in preclinical and
clinical settings. This chapter highlights on the ramification of some of the crucial
events that leads to the maturation of angiogenesis, explore the perplex process of
angiogenesis and discuss the amenable strategies for intervention. We will discuss
about the myriad number of current therapeutic agents based the target selectivity,
preclinical findings, clinical application, and toxicity profile.
Ang/Tie-2, Notch Signals, Pathological Angiogenesis, Toxicity
profile, Tumor Growth, Tumor Progression.
Rumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern University, Fort Lauderdale, Florida, USA.